drugset / Trial / NCT01527682

Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma

NCT01527682

NaSingle-groupOpen-labelTreatment

Summary

Objectives: The study will assess the ocular hypotensive effect of latanoprost and dorzolamide in a selected sample of patients affected by primary Pediatric Glaucoma (PG), refractory to surgical procedures. Safety will be assessed, too.In the first version of the protocol 96 eyes were forecasted to complete the enrolment. The protocol was then amended and now to complete the study 68 eyes should be included. This number of eyes could be achieved by recruiting from 34 to 68 patients due to not in all patients both eyes should be eligible for the study.

Timeline

Start
2009-07
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dorzolamide Small molecule 2 % Topical
Subject Latanoprost Small molecule 0.005 % Topical

Indications